Literature DB >> 18929114

Surgical alternative to trabeculectomy.

Roberto G Carassa1.   

Abstract

Non-penetrating glaucoma surgery, represented by deep sclerectomy and viscocanalostomy, is an effective method to lower intraocular pressure (IOP) in glaucomatous patients. Both procedures reduce IOP by allowing aqueous humor drainage without opening the anterior chamber. Deep sclerectomy, similar to trabeculectomy, provides aqueous external filtration in the subconjunctival space. This technique, with the adjunctive use of implants, antimetabolites, and goniopuncture, may provide final IOP comparable to those obtained with trabeculectomy, but with less complications. Viscocanalostomy is less dependent on external filtration since it increases trabecular aqueous outflow facility by micro-disrupting Schlemm's canal walls and juxtacanalicular trabecular meshwork. This technique is very safe, but it provides higher final IOPs compared to trabeculectomy. Non-penetrating surgery should be therefore considered a surgical alternative to trabeculectomy in specific clinical cases.

Entities:  

Mesh:

Year:  2008        PMID: 18929114     DOI: 10.1016/S0079-6123(08)01118-7

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  3 in total

1.  A modified deep sclerectomy with or without external trabeculectomy: a comparative study.

Authors:  George Kitsos; Miltiades Aspiotis; Yannis Alamanos; Konstantinos Psilas
Journal:  Clin Ophthalmol       Date:  2010-06-24

2.  Results of a modified non-penetrating deep sclerectomy in the treatment of open angle glaucoma with or without cataract.

Authors:  George Kitsos; Miltiades Aspiotis; Yannis Alamanos; Konstantinos Psilas
Journal:  Clin Ophthalmol       Date:  2010-07-30

3.  European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options.

Authors: 
Journal:  Br J Ophthalmol       Date:  2017-06       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.